#1
#1 out of 1100.00%
business3h ago
Travere Therapeutics Secures Civorebrutinib Rights From Everest Medicines; $112.5M Upfront, $1.03B Milestones
- Travere Therapeutics and Everest Medicines struck an exclusive license for civorebrutinib outside China and parts of Asia, signaling a major regional expansion.
- The deal includes $112.5 million upfront and up to about $1.03 billion in milestones across up to five indications.
- Travere will lead development and commercialization in its territory with shared costs for global trials.
- A 10-year non-compete on BTK products in the field applies to the agreement.
- The deal becomes effective after HSR clearance and customary conditions.
- The collaboration supports Travere’s kidney disease pipeline by expanding BTK inhibitor opportunities outside specified regions.
Vote 0